Search
The updated dietary guidelines from the federal government have caused confusion, but MSK dietitians' recommendations have not changed: A diet that is mostly plant based is still considered the most healthy.
New MSK research finds the TCA cycle’s waste-management function may present an opportunity against cancer; shows how microplastics impair immune ‘housekeeping’ functions; reveals the way the protein TOX plays different roles in different immune cells; and identifies a new combination approach for treating advanced kidney cancer after immunotherapy.
Dr. Gary Deng of the Integrative Medicine Service helps separate the hype from the proven health benefits of mushroom supplements.
MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. While there is a significant threat to pediatric cancer research stemming from COVID-19’s impact on philanthropy, several organizations helped MSK recognize pediatric cancer awareness month by fundraising for MSK Kids.
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.
Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.
Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.
Two of the year's top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.
Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.